Photo from David Steensma/X
Nov 12, 2023, 17:42
David Steensma: Our proteomics analysis of the large CANTOS CV trial is now online Blood Advances
David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter.
“Our proteomics analysis of the large CANTOS CV trial is now online Blood Advances led by Janghee Woo (now Winship Cancer Institute of Emory). Clonal hematopoiesis was associated with incident anemia and markers of inflammation which were attenuated by IL-1b inhibitor therapy.”
Source: David Steensma/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28